home > ict > autumn 2015 > the last mile


Dear guest!

article: The Last Mile
format: Adobe Acrobat PDF file
cost: £


News and Press Releases

European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Paris, November 4, 2022. The European Commission has approved Beyfortus® (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. RSV is a common and highly contagious seasonal virus, infecting nearly all children by the age of two. Beyfortus is the first and only single-dose RSV protective option for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions. Beyfortus is being developed jointly by Sanofi and AstraZeneca.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement